These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Muriel AC, Frank RG. Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411 [Abstract] [Full Text] [Related]
7. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary. Linton A, Bacon T, Peterson M. J Manag Care Pharm; 2009 Apr; 15(1):42-54. PubMed ID: 19125549 [Abstract] [Full Text] [Related]
8. The Effect of Florida Medicaid's State-Mandated Formulary Provision on Prescription Drug Use and Health Plan Costs in a Medicaid Managed Care Plan. Munshi KD, Mager D, Ward KM, Mischel B, Henderson RR. J Manag Care Spec Pharm; 2018 Feb; 24(2):124-131. PubMed ID: 29384030 [Abstract] [Full Text] [Related]
9. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults. Pauly NJ, Brown JD. J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965 [Abstract] [Full Text] [Related]
11. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, Dirstine J, Avorn J, Asch SM. Arch Intern Med; 2006 Feb 13; 166(3):332-7. PubMed ID: 16476874 [Abstract] [Full Text] [Related]
12. Impact of a text messaging pilot program on patient medication adherence. Foreman KF, Stockl KM, Le LB, Fisk E, Shah SM, Lew HC, Solow BK, Curtis BS. Clin Ther; 2012 May 13; 34(5):1084-91. PubMed ID: 22554973 [Abstract] [Full Text] [Related]
13. Impact of cost sharing on prescription drugs used by Medicare beneficiaries. Goedken AM, Urmie JM, Farris KB, Doucette WR. Res Social Adm Pharm; 2010 Jun 13; 6(2):100-9. PubMed ID: 20511109 [Abstract] [Full Text] [Related]
17. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders. Panzer PE, Regan TS, Chiao E, Sarnes MW. Am J Manag Care; 2005 Oct 13; 11(12 Suppl):S370-9. PubMed ID: 16236019 [Abstract] [Full Text] [Related]
18. Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit. Spence MM, Hui R, Chan J. J Manag Care Pharm; 2006 Jun 13; 12(5):377-82. PubMed ID: 16792444 [Abstract] [Full Text] [Related]
19. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Fairman KA, Motheral BR, Henderson RR. Clin Ther; 2003 Dec 13; 25(12):3147-61; discussion 3144-6. PubMed ID: 14749153 [Abstract] [Full Text] [Related]
20. Prescription co-pay reduction program for diabetic employees. Nair KV, Miller K, Park J, Allen RR, Saseen JJ, Biddle V. Popul Health Manag; 2010 Oct 13; 13(5):235-45. PubMed ID: 20879904 [Abstract] [Full Text] [Related] Page: [Next] [New Search]